S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3- phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at α1- and α2-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 38-53

  Millan, Mark J ^a,c   Gobert, Alain ^a   Newman Tancredi, Adrian ^a   Lejeune, Françoise ^a   Cussac, Didier ^a   Rivet, Jean Michel ^a   Audinot, Valérie ^a   Adhumeau, Agnès ^a   Brocco, Mauricette ^a   Nicolas, Jean Paul ^a   Boutin, Jean A ^a   Despaux, Nicole ^b   Peglion, Jean Louis ^b  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [4 (6 FLUORO 1,2 BENZISOXIZOL 3 YL)PIPERID 1 YL]ETHYL]3 PHENYL IMIDAZOLIN 2 ONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; CALCIUM ION; CORTICOSTERONE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MITOGEN ACTIVATED PROTEIN KINASE; NEUROLEPTIC AGENT; NORADRENALIN; SEROTONIN; SEROTONIN 2A ANTAGONIST; SULFUR 35; UNCLASSIFIED DRUG;

ADRENERGIC NERVE CELL; ADRENERGIC TRANSMISSION; AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CHO CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHERMIA; LOCUS CERULEUS; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR AFFINITY; SEROTONINERGIC TRANSMISSION; SUBSTANTIA NIGRA;

ADRENERGIC ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CALCIUM; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; IMIDAZOLES; ISOXAZOLES; MALE; NOREPINEPHRINE; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 0033976615     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Aghajanian GK, Cedarbaum JM and Wang RY (1977) Evidence for a norepinephrine-mediated collateral inhibition of locus coeruleus neurons. Brain Res 136:570-577.
2. Arnsten AFT (1997) Catecholamine regulation of the prefrontal cortex. J Psychopharmacology 11:151-162.
3. Bakshi VP and Geyer MA (1997) Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther 283:665-674.
4. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E and Cohen, BM (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 60:12-16.
5. 2-adrenoceptor subtypes in post-mortem human brain. J Psychopharmacol 12: 151-154.
6. Boess FG and Martin IL (1994) Molecular biology of 5-HT receptors. Neuropharmacology 33:275-317.
7. 1B agonist into the dorsal subiculum: Implications for schizophrenia. J Psychopharmacol 12:258-267.
8. Brunello N, Masotto C, Steardo L, Markstein R and Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177-213.
9. Coull JT, Frith CD, Dolan RJ, Frackowiak RSJ and Grasby PM (1997) The neural correlates of the noradrenergic modulation of human attention, arousal and learning. Eur J Pharmacol 9:589-598.
10. Cunningham-Owens DC (1996) Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 51:895-930.
11. Cussac D, Newman-Tancredi A, Pasteau V and Millan MJ (1998) Human dopamine D3 receptors stimulate MAP kinase phosphorylation in CHO cells. Soc Neurosci Abstr 24:1373.
12. Darracq L, Blanc G, Glowinski J and Tassin JP (1998) Importance of the noradrenaline-doparaine coupling in the locomotor activating effects of D-amphetamine. J Neurosci 18:2729-2739.
13. De Beaurepaire R, Labelle A, Naber D, Jones BD and Barnes TRE (1995) An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology 121:323-327.
14. 2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 37:265-272.
15. Elman I, Goldstein DS, Eisenhofer G, Folio J, Malhotra AK, Adler CM, Pickar D and Breier A (1999) Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology 20:29-34.
16. Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Bruinvels AT, Geisse S, Sommer B, Hoyer D, Tricklebank M and Schoeffter P (1998) The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor. Br J Pharmacol 124:889-896.
17. 2 antagonism in extrapyramidal functions. Br J Psychiatry 160:34-37.
18. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275:899-913.
19. Gobert A, Rivet J-M, Audinot V, Newman-Tancredi A, Cistarelli L and Millan MJ (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience 84:413-429.
20. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse, in press.
21. Gray AM and Connick JH (1998) Clozapine-induced dopamine levels in the rat striatum and nucleus accumbens are not affected by muscarinic antagonism. Eur J Pharmacol 362:127-136.
22. Gresch PJ, Sved AF, Zigmond MJ and Finlay JM (1995) Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65:111-116.
23. 3 receptors and use of antipsychotics in patients with schizophrenia. Arch Gen Psychiatry 54:225-231.
24. Josselin SA, Miller R and Beninger RJ (1997) Behavioural effects of clozapine and dopamine receptor subtypes. Neurosci Biobehav Rev 21:531-558.
25. 2-adrenoceptor antagonism in the anti-cataleptic properties of the typical neuroleptic agent, clozapine, in the rat. Br J Pharmacol 124:1550-1556.
26. 1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121:309-316.
27. Kenakin T (1997) Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven, Philadelphia/New York.
28. Kinon BJ and Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs: A critical analysis. Psychopharmacology 124:2-34.
29. Knable MB and Weinberger DR (1997) Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacology 11:123-131.
30. 3 receptor mutant mice. J Neurosci 18:2231-2238.
31. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 54:567-572.
32. Kuroki T, Meltzer HY and Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781.
33. 3H-]NGD-94-1 study. Mol Psychiatry 3:528-533.
34. 1-adrenergic receptors demonstrated by in vivo voltammetry. Brain Res 460:398-401.
35. 1A receptors. Eur J Pharmacol 260:79-83.
36. 1A receptors and their modulation of the activity of serotonergic and dopaminergic neurons in the rat. J Pharmacol Exp Ther 280:1241-1249.
37. 3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
38. Litman RE, Su TP, Potter WZ, Hong WW and Pickar D (1996) Idazoxan and response to the atypical neuroleptic, clozapine. Br J Psychiatry 168:571-579.
39. Maes JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleschi E and Weintraub S (1993) Studies of catecholamine metabolism in schizophrenia/ psychosis-I. Neuropsychopharmacology 8:97-109.
40. Martin P, Svensson A, Carlsson A and Carlsson ML (1994) On the roles of dopamine D-1 vs D-2 receptors for the hyperactivity response elicited by MK-801. J Neural Transm 95:113-121.
41. 2A receptors. Eur J Pharmacol 280:R9-R11.
42. McCormick DA and Pape HC (1995) Noradrenergic and serotonergic modulation of a hyperpolarization-activated cation current in thalamic relay neurons. J Physiol 431:319-342.
43. Meltzer HY (1995) Atypical antipsychotic drugs, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1277-1286, Raven Press, New York.
44. 2A-adrenergic receptor agonist, S 18616. Adv Pharmacol 42:575-579.
45. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NE), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953-955.
46. 1A agonist properties. I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 286:1341-1355.
47. 4 receptors: An in vitro and in vivo comparison with L-745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. J Pharmacol Exp Ther 287: 167-186.
48. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885-898.
49. Missale C, Nash SR, Robinson SW, Jaber M and Caron MG (1998) Dopamine receptors: From structure to function. Physiol Rev 78:189-225.
50. 4·4 receptors: Actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282:181-191.
51. 2 adrenoceptor-mediated G protein activation in amygdala and lateral septum. Neuropharmacology, in press.
52. 35S]GTPγS binding and antibody study. Mol Pharmacol 55:564-574.
53. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol 8:193-195.
54. Parellada E, Catafau AM, Bernardo M, Lomeña F, Catarineu S and González-Monclús E (1998) The resting and activation issue of hypofrontality: A single photon emission computed tomography study in neuroleptic naive and neuroleptic-free schizophrenic patients. Biol Psychiatry 44:787-790.
55. 2C, receptors provoke corticosterone (CS) secretion in rats. Soc Neurosci Abstr 23:976.
56. 2A receptors. Proceedings of the 6th International Conference on In Vivo Methods, pp 277-278, Stony Brook, NY.
57. Roth BL and Meltzer HY (1995) The role of serotonin in schizophrenia, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1215-1228, Raven Press, New York.
58. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368.
59. 1-Adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: A microdialysis study. Eur J Pharmacol 261:59-64.
60. 2A receptors in antipsychotic activity. Life Sci 56:2209-2222.
61. 7 receptors may have clinical potential and the development of selective compounds to examine these possibilities is highly desirable. Drugs News Perspect 10:214-224.
62. 1-adrenoceptor antagonism. J Clin Psychopharmacol 15:11S-18S.
63. 3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. J Neurosci 17:2519-2530.
64. Westerink BHC, De Boer P, Kwint HF, DeVries JB, Kruse CG and Long SK (1998) Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 361:27-33.
65. 4 receptor ligands: Relation to antipsychotic action. Eur J Pharmacol 351:273-286.
66. 3 receptor-selective agonists and antagonists. Synapse 31:210-215.